High-dose omega-3 eicosapentaenoic acid (EPA) reduced the risk of death by approximately 30% compared to placebo in patients with colorectal cancer liver metastases (CRLM) after resection surgery, according to results of the phase III EMT2 trial presented at the ESMO Congress 2026 (Abstract LBA30).
November 4th, 2026
Read moreThe antibody–drug conjugate (ADC) sonesitatug vedotin (Sone-Ve) improved overall survival (OS) compared with standard therapy in patients with previously treated advanced CLDN18.2-positive gastric or gastroesophageal cancer. This is the first time a CLDN18.2-targeting ADC has shown an OS benefit in a phase III trial in this disease.
November 4th, 2026
Read morePembrolizumab monotherapy significantly improved progression-free survival (PFS) compared with carboplatin-paclitaxel chemotherapy in patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma, according to phase III KEYNOTE-C93/GOG-3064/ENGOT-en15 findings presented at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract LBA12) and published simultaneously in The Lancet.
November 4th, 2026
Read moreAn all-oral targeted therapy combination of osimertinib and savolitinib significantly improved progression-free (PFS) and overall survival (OS) compared with platinum–pemetrexed chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) whose tumors had MET overexpression and/or amplification and whose disease progressed following osimertinib, according to results from the phase III SAFFRON trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract LBA6).
November 2nd, 2026
Read moreA perioperative treatment regimen combining durvalumab with enfortumab vedotin (EV) improved event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or declined cisplatin-based chemotherapy, according to results from the phase III VOLGA trial highlighted at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract LBA2). The findings were simultaneously published in The New England Journal of Medicine (2026; doi.org/10.1056/NEJMoa2608323).
November 2nd, 2026
Read moreAdding the bispecific T-cell engager drug tarlatamab to durvalumab (durva) as first-line maintenance following initial therapy helped patients with extensive-stage small cell lung cancer (ES-SCLC) better control their disease, manage side effects and live longer, according to a global DeLLphi-305 patient study.
November 2nd, 2026
Read morePatients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC) lived longer with the oral investigational drug divarasib than with existing approved targeted therapies sotorasib and adagrasib, according to results presented at the 2026 ESMO Congress in Madrid, Spain (Abstract LBA5).
November 3rd, 2026
Read morePatients with previously untreated advanced biliary tract cancer (BTC) who received ivonescimab plus chemotherapy experienced significant improvements in overall (OS) and progression-free survival (PFS) as well as objective response rate (ORR) compared to those who were treated with durvalumab plus chemotherapy, according to findings from the phase III HARMONi-GI1 trial presented during the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract LBA8).
November 3rd, 2026
Read morePatients with previously treated small cell lung cancer (SCLC) who received tarlatamab continued to experience improved survival compared with those treated with chemotherapy, according to extended follow-up findings from the phase III DeLLphi-304 trial presented during the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 3808O). The findings were simultaneously published in Annals of Oncology.
November 3rd, 2026
Read more